MariMedMRMD -2.21% PB Ratio is 0.57 as of Jul. 01, 2026, which is 87% below its 10-year median of 4.30. The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, MariMed ranks better than 89.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-01), MariMed's share price is $0.06855. MariMed's Book Value per Share for the quarter that ended in Mar. 2026 was $0.12. Hence, MariMed's PB Ratio of today is 0.57.
Good Sign:
MariMed Inc stock PB Ratio (=0.58) is close to 1-year low of 0.55.
The historical rank and industry rank for MariMed's PB Ratio or its related term are showing as below:
MRMD'
s PB Ratio Range Over the Past 10 Years
Min: 0.45 Med: 4.3 Max: 273.33
Current: 0.57
During the past 13 years, MariMed's highest PB Ratio was 273.33. The lowest was 0.45. And the median was 4.30.
MRMD's PB Ratio is ranked better than 89.35% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.89
vs MRMD: 0.57
During the past 12 months, MariMed's average Book Value Per Share Growth Rate was -22.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 28.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of MariMed was 89.70% per year. The lowest was -96.40% per year. And the median was -8.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
MariMed PB Ratio Related Terms
MariMed PB Ratio Historical Data
* Premium members only.
The historical data trend for MariMed's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's PB Ratio distribution charts can be found below:
* The bar in red indicates where MariMed's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
MariMed's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
MariMed (MRMD) has a PB Ratio of 0.57 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MariMed and its competitors. This is 87% below median its historical median of 4.30. Over the past decade, MariMed's PB Ratio has ranged from 0.45 to 273.33. According to the industry distribution chart, MariMed ranks #98 out of 920 companies in the Drug Manufacturers industry, placing it in the top 10.7%.
Is MariMed's PB Ratio too high?
MariMed's current PB Ratio of 0.57 is 87% below median its 10-year median of 4.30. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 273.33. The Drug Manufacturers industry median PB Ratio is 1.89. MariMed's value of 0.57 is 69.8% below this industry median. Based on the distribution chart, MariMed ranks #98 out of 920 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MariMed's PB Ratio compare to RMTI and CPHI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #98 out of 920 companies for PB Ratio. This places MariMed in the top 11% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.89. MariMed's value of 0.57 is 69.8% below this benchmark. Historically, MariMed's own PB Ratio has ranged from 0.45 to 273.33 over the past decade. While the company's 10-year median is 4.30 vs. the industry median of 1.89, MariMed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.89, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MariMed's current PB Ratio of 0.57 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current PB Ratio is 0.57, which is 87% below median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 57.2% below its estimated fair value. The current PB Ratio is 0.57, which is 87% below median its 10-year median of 4.30 and 69.8% below the Drug Manufacturers industry median of 1.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For MariMed (MRMD), the current PB Ratio is 0.57 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 